InsidersTradesSigma
AdaptHealth Corp.: insider trades · United States · SEC (Form 4)
SEC:adapthealth-corpUS·SEC (Form 4)Mcap 1.5Bn€Healthcare & Pharma
Discover the full management transaction log of AdaptHealth Corp., a publicly traded company based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, AdaptHealth Corp. has published 121 public disclosures. Market capitalisation: €1.5bn. The latest transaction was reported on 28 April 2026 — Retenue fiscale. Among the most active insiders: Prast Albert A.. The full history is free.
121
Insider Decl.
0
Thresholds
€23m
28 ops.
Buy Volume
€2m
4 ops.
Sell Volume
Financial data
10.66 €
Analyst consensus
8 analystsBuy
11.00 €Target 14.00 €(+31%)18.00 €
Valuation
PER (forward)9.1x
P/Book0.9x
Beta1.57
Balance sheet & cash
Market cap1.45 Bn€
Debt / Equity132%
Profitability & ownership
ROE-4.8%
ROA2.6%
% insiders8.1%
% institutions107.0%
Last declaration on 28 April 2026
Declarations121 total
Executives●Retenue fiscale27SEC
US$521,83258,203 shares@ US$8.96570.036% mcap100.0% of flow
Common Stock
SEC:0001104659-26-050577·
Executives●Retenue fiscale26SEC
€521,83258,203 shares@ €8.96570.036% mcap49.7% of flow
Common Stock
SEC:0001104659-26-050577:0·
Executives▲Purchase31SEC
US$7m820,528 shares@ US$8.37440.47% mcap99.9% of flow
Common Stock
SEC:0001193125-26-132663·
Ideal exit: 5 Dec 2026 (T+270)
Executives▲Purchase15SEC
US$6,304727 shares@ US$8.67170.0004% mcap0.1% of flow
Common Stock
SEC:0001193125-26-132703·
Ideal exit: 14 Dec 2026 (T+270)
Executives▲Purchase16SEC
€6,304727 shares@ €8.67170.0004% mcap0.0% of flow
Common Stock
SEC:0001193125-26-132703:0·
Ideal exit: 14 Dec 2026 (T+270)
Executives▲Purchase27SEC
€7m820,528 shares@ €8.37440.47% mcap50.0% of flow
Common Stock
SEC:0001193125-26-132663:0·
Ideal exit: 5 Dec 2026 (T+270)
Executives◆Grant17SEC
014,970 shares0
Common Stock
SEC:0001104659-22-074326:0·
Executives◆Grant17SEC
09,321 shares0
Common Stock
SEC:0001104659-22-074330:0·
Executives◆Grant17SEC
09,321 shares0
Common Stock
SEC:0001104659-22-074325:0·
Executives◆Grant17SEC
09,321 shares0
Common Stock
SEC:0001104659-22-074329:0·
Executives◆Grant17SEC
010,451 shares0
Common Stock
SEC:0001104659-22-074332:0·
Executives◆Grant17SEC
09,321 shares0
Common Stock
SEC:0001104659-22-074335:0·
Executives▲Purchase◆Signal · 51SEC
€2m100,000 shares@ €15.91250.11% mcap100.0% of flow
Common Stock
SEC:0000899243-22-023344:0·
Ideal exit: 13 Mar 2023 (T+270)
Executives▲Purchase44SEC
€1,623100 shares@ €16.23470.0001% mcap100.0% of flow
Common Stock
SEC:0000899243-22-022818:0·
Ideal exit: 11 Mar 2023 (T+270)
Executives▲Purchase◆Signal · 52SEC
€2m100,000 shares@ €16.53370.11% mcap32.5% of flow
Common Stock
SEC:0000899243-22-022559:0·
Ideal exit: 10 Mar 2023 (T+270)
Executives▲Purchase42SEC
€98,8505,999 shares@ €16.47770.0068% mcap1.9% of flow
Common Stock
SEC:0000899243-22-022193:0·
Ideal exit: 6 Mar 2023 (T+270)
Executives▲Purchase◆Signal · 47SEC
€578,64735,091 shares@ €16.48990.040% mcap11.4% of flow
Common Stock
SEC:0000899243-22-021040:0·
Ideal exit: 26 Feb 2023 (T+270)
Executives▲Purchase42SEC
€3,275200 shares@ €16.37560.0002% mcap0.1% of flow
Common Stock
SEC:0000899243-22-019927:0·
Ideal exit: 19 Feb 2023 (T+270)
Executives▲Purchase◆Signal · 52SEC
€2m100,000 shares@ €16.3810.11% mcap32.2% of flow
Common Stock
SEC:0000899243-22-019372:0·
Ideal exit: 14 Feb 2023 (T+270)
Executives▲Purchase43SEC
€335,76021,632 shares@ €15.52150.023% mcap6.6% of flow
Common Stock
SEC:0000899243-22-018602:0·
Ideal exit: 10 Feb 2023 (T+270)
Executives▲Purchase29SEC
€350,76624,652 shares@ €14.22870.024% mcap6.9% of flow
Common Stock
SEC:0000899243-22-018138:0·
Ideal exit: 6 Feb 2023 (T+270)
Executives▲Purchase43SEC
€142,6967,000 shares@ €20.38510.0098% mcap24.3% of flow
Common Stock
SEC:0001104659-22-059501:0·
Ideal exit: 11 Feb 2022 (T+270)
Executives▲Purchase40SEC
€246,08217,486 shares@ €14.07310.017% mcap4.8% of flow
Class A Common Stock
SEC:0000899243-22-011073:0·
Ideal exit: 6 Dec 2022 (T+270)
25 of 121 declarations
About AdaptHealth Corp.
AdaptHealth Corp. (ticker: AHCO) is a United States-listed healthcare company traded on the NASDAQ, not the NYSE. Headquartered in Conshohocken, Pennsylvania, United States, the company has built itself into a national player in home-based healthcare solutions, with a core focus on home medical equipment, medical supplies, and related services. Its business model is centered on supporting patients after hospital discharge or following a physician referral, helping extend care into the home while improving adherence, convenience, and overall cost efficiency. ([adapthealth.com](https://adapthealth.com/2026/02/24/adapthealth-corp-announces-fourth-quarter-and-full-year-2025-results-and-provides-2026-financial-guidance/?utm_source=openai)) AdaptHealth reports four business segments that align with its product categories: Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home. This structure gives the company exposure to several durable healthcare demand pools, including sleep apnea and respiratory therapy, diabetes care and glucose monitoring, and broader home wellness and care-at-home solutions. The company’s portfolio includes continuous glucose monitoring devices, insulin pumps, respiratory devices and supplies, and other home-based medical products and services. Management positions AdaptHealth as a nationwide network of trusted medical equipment providers, combining clinically focused products, technology, and patient support. ([adapthealth.com](https://adapthealth.com/investorrelations/corporate-profile/?utm_source=openai)) From a competitive standpoint, AdaptHealth operates in a highly fragmented but competitive market, facing national and regional rivals such as Owens & Minor, Lincare, Rotech, Cardinal Health, and Quipt Home Medical, among others. Its strategic edge lies in scale, geographic reach, and the ability to serve multiple product categories through a broad operational platform. As of year-end 2025, the company said it served approximately 4.3 million patients annually across 48 states, underscoring its broad U.S. footprint and national distribution network. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1725255/000162828025007740/ahco-20241231.htm?utm_source=openai)) Recent developments have centered on balance-sheet repair and operational simplification. In 2025, the company completed the sale of certain non-core infusion assets to help reduce debt, and in November 2025 S&P Global Ratings upgraded the issue-level rating on AdaptHealth’s senior unsecured debt. In February 2026, AdaptHealth reported full-year 2025 results and issued 2026 guidance, highlighting operating cash flow growth, record patient census in several categories, and the acquisition of a leading HME provider in Hawaii, which expanded the company’s footprint to its 48th state. For investors, AHCO is therefore a healthcare-at-home name with meaningful scale and structural tailwinds, but one that remains sensitive to reimbursement dynamics, patient volumes, and execution on its capital structure. ([adapthealth.com](https://adapthealth.com/blogs/latest-news/adapthealth-corp-closes-transaction-to-dispose-of-certain-home-infusion-assets-and-reduces-debt?utm_source=openai))
